Supaglutide - Innogen Pharmaceutical Technology
Alternative Names: Diabegone; Supaglutide injection - Shanghai Innogen Pharmaceutical TechnologyLatest Information Update: 29 Aug 2024
At a glance
- Originator St. Michaels Hospital; University of Toronto
- Developer Yinnuo Pharmaceutical Technology
- Class Antihyperglycaemics; Recombinant fusion proteins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Type 2 diabetes mellitus
Most Recent Events
- 21 Jun 2024 Pharmacokinetics data from a phase I trial in Type 1 diabetes mellitus (In Volunteers) presented at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA-2024)
- 02 Oct 2023 Adverse events and efficacy data from a phase-II/III trial in Type 2 diabetes mellitus presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
- 02 Oct 2023 Adverse events and efficacy data from a phase-II/III trial in Type 2 diabetes mellitus presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)